MedTrace Logo

LTFU for All Cell and Gene Therapy Studies

NCT06194461 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2025-06-27

No results posted yet for this study

Summary

Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.

Conditions

Interventions

BIOLOGICAL

AZD5851

Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.

BIOLOGICAL

AZD0754

Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2041-11-29
Completion
2041-11-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06194461 on ClinicalTrials.gov